drug
cyclophosphamide
Marketedupdated 3mo agoby Long Grove Pharmaceuticals LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagDLBCL6 co-mentions · 3 sources
- tagOncology5 co-mentions · 4 sources
- tagCLL4 co-mentions · 1 sources
- companySandoz Inc2 co-mentions · 1 sources
- tagHematology2 co-mentions · 1 sources
- companyCity of Hope1 co-mentions · 1 sources
- companyNational Cancer Institute US1 co-mentions · 1 sources
- companyGeneral Hospital of the People's Liberation Army1 co-mentions · 1 sources
indications
investigational
Breast CancerDLBCL
all catalysts(3)
phase 1 2 completion · 2
Trials studying cyclophosphamide
- phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- phase1A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis
- phase3A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- phase3A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- phase2CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
- phase2A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
- phase2A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- phase2A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 26, 2035
~8.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Feb 15, 2036formulationUS 10993952
- Feb 15, 2036formulationUS 10993952
- Feb 15, 2036formulationUS 10993952
- Feb 15, 2036formulationUS 12329767
- Feb 15, 2036formulationUS 12329767
- Feb 15, 2036formulationUS 12329767
- Dec 1, 2035formulationUS 11382923
- Dec 1, 2035formulationUS 11382923
- Dec 1, 2035formulationUS 11382923
- Jul 13, 2035formulationUS 10849916
- Jul 13, 2035formulationUS 10849916
- Jul 13, 2035formulationUS 10849916
- Jun 26, 2035formulationUS 9662342
- Jun 26, 2035formulationUS 9662342
- Jun 26, 2035formulationUS 9662342
News(4)
- Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate MatterJuly 24, 2026 - Taoyuan City, Taiwan - Sunny Pharmtech, Inc is voluntarily recalling three lots of Cyclophosphamide for Injection, USP, 1g/vial and 2g/vial, to the User Level due to the presence of…fda_medwatch · 19d ago
- Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast CancerTreatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.onclive · 3mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 3mo ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 3mo ago
Data sources
last refreshed 33m ago
Found something off?
comments(0)
5-min edit window · permanent after that